BLT Announces Health Canada approval for BLIS M18 Probiotic

Blis Technologies Announces Health Canada approval for BLIS M18(TM) Probiotic Blis Technologies announces Health Canada approval of BLIS M18(TM) probiotic for use in Health Products with specific and substantial claims. After reviewing supporting science and safety publications, Health Canada has approved products containing BLIS M18(TM) to include claims such as, "promotes oral health [through the re-colonisation of the oral cavity]", "helps decrease build-up of dental plaque", "helps prevent gingivitis and plaque build-up in conjunction with good oral hygiene", "aids in gum healing". Brian Watson, CEO of Blis Technologies, said we have had a push on obtaining regulatory approvals in key markets and this is another success from this effort which can have long lead times. "These regulatory approvals provide access to new markets with Canada representing an attractive target for future sales. We now have both BLIS K12(TM) and BLIS M18(TM) approved in Canada with substantial label claims and we will be accelerating our sales plans for this attractive market". For further comment contact: Brian Watson Chief Executive Officer 027 705 9133 About Blis Technologies Ltd Delivering proven health benefits through evidence-based, advanced probiotics Blis is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support and teeth and gum health. BLIS products are sold throughout New Zealand and in Australia, Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at www.blis.co.nz. End CA:00334245 For:BLT Type:MKTUPDTE Time:2019-05-08 12:01:10